A number of specialty pharmaceutical funds supported Xialepu Biotech's Hong Kong stock market and attracted attention

Feb 9, 2022 14:07

ADC giant Lepu Biotech passed the Hong Kong Stock Exchange hearing: multiple ADCs are expected to be the world's first under a differentiated layout

It is the only innovative drug company in China that has both a PD-1 monoclonal antibody in the NDA reporting stage and multiple clinical phase II ADC pipelines.

IPO早知道Feb 8, 2022 08:54

Weekly IPO | SPAC initiated by Li Ning submitted the form, and Huitongda is in the process of offering shares

A total of 8 IPOs were submitted to the Main Board and 1 IPO was posted this week; VSPN, the world's largest e-sports operator, went to Hong Kong for an IPO, with revenue of 1,322 billion yuan in 9 months; two new SPACs were added to the Hong Kong Stock Exchange this week.

富途資訊Feb 5, 2022 22:20

Lepu Biotech has passed the Hong Kong Stock Exchange hearing and will soon be listed as an IPO in Hong Kong

Lepu Biotech was founded in 2018. As a biopharmaceutical company focusing on the field of cancer treatment, it has now built multiple oncology product pipelines.

瑞恩資本RyanbenCapitalFeb 4, 2022 17:10

Oncolytic virus CG0070 achieved 100% CR in high-risk bladder cancer patients. China Lepu Biotech has received clinical approval

Recently (November 13, 2021), CG Oncology revealed impressive phase II clinical trial data for its oncolytic virus drug CG0070 combined with K drug. The trial results showed that among the nine non-muscle-invasive bladder cancer (NMIBC) patients who did not respond to BCG vaccine (BCG) whose efficacy could be assessed, all patients achieved complete remission (CR) at 3 months. Furthermore, the CR rate of patients who reached the 6-month evaluation point and the 9-month evaluation point also remained 100%. NMIBC is in urgent need of new treatments Bladder cancer is one of the common malignant tumors of the urinary system (NMIBC in

新浪醫藥Nov 16, 2021 18:05

Can Lepp Bios rely on Putley to get his blood back in the PD-1 volume? |Wisdom · New Pharmaceuticals

　　Recently, the Hong Kong Stock Exchange revealed that the prospectus submitted by Lepu Biotechnology Co., Ltd. (hereinafter referred to as Lepu Biotech) on April 28 this year has expired. On October 26, Lepu Biotech submitted a marketing application for the second indication of its core product, PD-1 monoclonal antibody putrizumab injection, to CDE, which was accepted. According to the prospectus data, anti-PD-1 and anti-PD-L1 candidates are the cornerstone of Lepu bioimmunotherapy and are a pillar pipeline. At the beginning of July this year, the PD-1 monoclonal antibody puterizumab (HX008) submitted by Lepu Biotech was used as a second-line treatment for melanoma

和訊網Nov 1, 2021 08:30